openPR Logo
Press release

Graves Disease Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, F. Hoffmann-La Roche Ltd.,

05-13-2024 08:43 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Graves Disease Pipeline Drugs Analysis Report (2024 Updates):

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graves Disease pipeline constitutes 8+ key companies continuously working towards developing 10+ Graves Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Graves Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Disease Market.

The Graves Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Graves Disease Pipeline Report: https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Graves Disease treatment therapies with a considerable amount of success over the years.
• Graves Disease companies working in the treatment market are TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others, are developing therapies for the Graves Disease treatment
• Emerging Graves Disease therapies in the different phases of clinical trials are- Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others are expected to have a significant impact on the Graves Disease market in the coming years.
• In March 2023, Immunovant Sciences GmbH has commenced a trial called "An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)." This extension study consists of two cohorts, including an observational group and a treatment group, designed for individuals who have finished the feeder studies (IMVT-1401-3201 or IMVT-1401-3202).
• In June 2022, Sling Therapeutics, Inc., a biopharmaceutical firm, has initiated a Series A funding round of USD 35 million, spearheaded by TPG's The Rise Fund. The secured funds will bolster a Phase 2b clinical trial assessing the company's experimental medication, linsitinib, dedicated to addressing thyroid eye disease (TED). TED predominantly impacts women and commonly occurs among individuals with hyperthyroidism resulting from Graves' disease.
• In May 2022, Mindray introduced the TRAb assay, aimed at diagnosing and managing Graves' disease. The TRAb (thyrotropin receptor antibody) serves as the pathogenic antibody associated with Graves' disease and is recognized as one of the crucial serum biomarkers essential for diagnosis.

Graves Disease Overview
Graves' disease is an autoimmune disorder that causes hyperthyroidism, which is the overproduction of thyroid hormones by the thyroid gland. It is characterized by the body's immune system mistakenly attacking the thyroid gland, leading to excessive production of thyroid hormones. This condition can result in various symptoms, including weight loss, rapid heartbeat, sweating, nervousness, tremors, fatigue, heat intolerance, and protruding eyes (exophthalmos).

Get a Free Sample PDF Report to know more about Graves Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/graves-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Graves Disease Drugs Under Different Phases of Clinical Development Include:
• Research Program: TSHR Septerna
• Research Program: Cyclopeptides advanceCOR
• Research Program: EVOQ Therapeutics
• WP-1302: Worg Pharmaceuticals
• K1-70: AV7 Limited
• CFZ533: Novartis Pharmaceuticals
• Batoclimab: Immunovant Sciences GmbH

Graves Disease Route of Administration
Graves Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Graves Disease Molecule Type
Graves Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Graves Disease Pipeline Therapeutics Assessment
• Graves Disease Assessment by Product Type
• Graves Disease By Stage and Product Type
• Graves Disease Assessment by Route of Administration
• Graves Disease By Stage and Route of Administration
• Graves Disease Assessment by Molecule Type
• Graves Disease by Stage and Molecule Type
DelveInsight's Graves Disease Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Graves Disease product details are provided in the report. Download the Graves Disease pipeline report to learn more about the emerging Graves Disease therapies at:
https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Graves Disease Therapeutics Market include:
Key companies developing therapies for Graves Disease are - Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Institute of Isotopes Co. Ltd., bioMerieux SA, Horizon Therapeutics Ireland DAC, and others.

Graves Disease Pipeline Analysis:
The Graves Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Graves Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves Disease Treatment.
• Graves Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Graves Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Graves Disease drugs and therapies-
https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Disease Pipeline Market Drivers
• Increasing the prevalence of Graves Disease, increased public awareness about the treatment of Graves' disease are some of the important factors that are fueling the Graves Disease Market.

Graves Disease Pipeline Market Barriers
• However, high cost of the treatment, complications associated with the treatment and other factors are creating obstacles in the Graves Disease Market growth.

Scope of Graves Disease Pipeline Drug Insight
• Coverage: Global
• Key Graves Disease Companies: TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others
• Key Graves Disease Therapies: Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others
• Graves Disease Therapeutic Assessment: Graves Disease current marketed and Graves Disease emerging therapies
• Graves Disease Market Dynamics: Graves Disease market drivers and Graves Disease market barriers

Request for Sample PDF Report for Graves Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Graves Disease Report Introduction
2. Graves Disease Executive Summary
3. Graves Disease Overview
4. Graves Disease- Analytical Perspective In-depth Commercial Assessment
5. Graves Disease Pipeline Therapeutics
6. Graves Disease Late Stage Products (Phase II/III)
7. Graves Disease Mid Stage Products (Phase II)
8. Graves Disease Early Stage Products (Phase I)
9. Graves Disease Preclinical Stage Products
10. Graves Disease Therapeutics Assessment
11. Graves Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Graves Disease Key Companies
14. Graves Disease Key Products
15. Graves Disease Unmet Needs
16 . Graves Disease Market Drivers and Barriers
17. Graves Disease Future Perspectives and Conclusion
18. Graves Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Graves Disease Market https://www.delveinsight.com/report-store/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graves Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Graves Disease Epidemiology https://www.delveinsight.com/report-store/graves-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graves Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Graves Disease Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, F. Hoffmann-La Roche Ltd., here

News-ID: 3494705 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Disease

Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research. Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight: Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and